<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473339</url>
  </required_header>
  <id_info>
    <org_study_id>2020107</org_study_id>
    <nct_id>NCT04473339</nct_id>
  </id_info>
  <brief_title>A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation</brief_title>
  <official_title>A Randomized Prospective Trail of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Recurrent Ovarian Cancer Patients With Mutations in Homologous Recombination Repair (HRR) Genes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAI Hongbing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III prospective study with the primary objective to investigate the benefit of&#xD;
      Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in ovarian cancer patients with mutations&#xD;
      in homologous recombination repair (HRR) genes. The target population for this study is&#xD;
      patients with recurrent ovarian, peritoneal or fallopian tube cancers undergoing&#xD;
      Cytoreductive Surgery (CRS). Patients will be divided into two groups according to HRR genes&#xD;
      mutation, each group will be further divided into two sub-groups with different intervention.&#xD;
      Patients in Group A are HRR mutated type, sub-group 1 will undergo CRS plus HIPEC and then go&#xD;
      on to receive standard platinum-based combination doublet intravenous chemotherapy, sub-group&#xD;
      2 will undergo CRS and then go on to intravenous chemotherapy. Patients in Group B are HRR&#xD;
      wild type, sub-group 3 will undergo CRS plus HIPEC and then go on to receive standard&#xD;
      platinum-based combination doublet intravenous chemotherapy, sub-group 4 will undergo CRS and&#xD;
      then go on to intravenous chemotherapy. All patients will receive maintenance therapy with&#xD;
      Niraparib after primary treatment. Prognostic information will be collected for investigation&#xD;
      of survival benefits of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to 36 months since diagnosis</time_frame>
    <description>The progression-free survival interval was the time between diagnosis and evidence of recurrent or progressive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 36 months since histological diagnosis</time_frame>
    <description>The overall survival interval was the time between diagnosis and death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DP9</measure>
    <time_frame>the 1 day of histological diagnosis and 9 months after</time_frame>
    <description>The 9 months progression-free survival rate was the rate of no evidence of recurrent or progressive disease at the time of 9 months since histological diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DP12</measure>
    <time_frame>the 1 day of histological diagnosis and 12 months after</time_frame>
    <description>The 9 months progression-free survival rate was the rate of no evidence of recurrent or progressive disease at the time of 12 months since histological diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events, SAEs</measure>
    <time_frame>surgery and with in 30 days</time_frame>
    <description>Serious adverse events occur within 30 days after surgery, measured with CTCAE 4.0</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Ovarian Cancer, Epithelial</condition>
  <condition>Hyperthermic Intraperitoneal Chemotherapy(HIPEC)</condition>
  <condition>Homologous Recombination Repair Gene Mutation</condition>
  <arm_group>
    <arm_group_label>HRR mt 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are HRR mutated type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRR mt 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are HRR mutated type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRR wt 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are HRR wild type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRR wt 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are HRR wild type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRS+HIPEC</intervention_name>
    <description>Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.&#xD;
A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS.</description>
    <arm_group_label>HRR mt 1</arm_group_label>
    <arm_group_label>HRR wt 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRS alone</intervention_name>
    <description>Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.</description>
    <arm_group_label>HRR mt 2</arm_group_label>
    <arm_group_label>HRR wt 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-75&#xD;
&#xD;
          -  Karnofsky performance status &gt;50 or World Health Organization performance score &lt; 2&#xD;
&#xD;
          -  primary or recurrence ovarian, peritoneal or fallopian tube epithelial cancer; first&#xD;
             intra-abdominal recurrence without distant metastasis (including: unique resectable&#xD;
             pleural metastasis which are platinum-sensitive; resectable single lymphatic&#xD;
             metastasis retroperitoneal or inguinal)&#xD;
&#xD;
          -  preoperative platinum-based chemotherapy (carboplatin and paclitaxel, carboplatin and&#xD;
             liposomal doxorubicin, gemcitabine, trabectedin or topotecan)&#xD;
&#xD;
          -  lesion can be removed completely or residual disease &lt; 0.5 cm&#xD;
&#xD;
          -  last chemotherapy finished no more than 12 weeks after surgery&#xD;
&#xD;
          -  no hepatic function damage&#xD;
&#xD;
          -  white blood cell count ≥3.5*10^9/L; platelet count ≥80*10^9/L; Hemoglobin ≥90g/L&#xD;
&#xD;
          -  no contraindication of surgery and anesthesia&#xD;
&#xD;
          -  life expectancy ≥ 3 months&#xD;
&#xD;
          -  informed consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 or &gt;75&#xD;
&#xD;
          -  no history of other cancer&#xD;
&#xD;
          -  platinum allergy&#xD;
&#xD;
          -  distant metastasis&#xD;
&#xD;
          -  used anti-angiogenic drug within 8 weeks&#xD;
&#xD;
          -  possibility of more than two resection of alimentary canal&#xD;
&#xD;
          -  recurrence &lt; 6 months after primary treatment&#xD;
&#xD;
          -  histologic type: non epithelial origin&#xD;
&#xD;
          -  infection out of control&#xD;
&#xD;
          -  follow-up unable to carry on (geographic or psychic)&#xD;
&#xD;
          -  cardiac insufficiency or respiratory insufficiency&#xD;
&#xD;
          -  has received HIPEC already&#xD;
&#xD;
          -  being in other clinical study&#xD;
&#xD;
          -  pregnancy or lactation period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongbing Cai, Doctor</last_name>
    <phone>+86-27-67812648</phone>
    <email>chb2105@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen Li, Doctor</last_name>
    <phone>+86-27-67812648</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanzhen Zhang, Doctor</last_name>
      <phone>+86-27-67812787</phone>
      <email>znyyll@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 12, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhongnan Hospital</investigator_affiliation>
    <investigator_full_name>CAI Hongbing</investigator_full_name>
    <investigator_title>Dr. Prof.</investigator_title>
  </responsible_party>
  <keyword>Homologous Recombination Repair Gene Mutation</keyword>
  <keyword>hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

